A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to ...

Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in ...

Sponsored by B/Bauer Hair Lounge It started because she had alopecia and was turned away from salons – now Brooke Bauer is empowering other women who experience hair loss, to find the right ...

Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.

Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.